Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Feature Review Papers on Advanced Gastric Cancer
share announcement

Feature Review Papers on Advanced Gastric Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 30 April 2024 | Viewed by 4029

Special Issue Editors

Prof. Dr. Yasuhide Yamada

E-Mail Website
Guest Editor
Comprehensive Cancer Center, National Center for Global Health and Medicine, Tokyo 162-8655, Japan
Interests: gastric cancer; colorectal cancer
Dr. Naoki Takahashi

E-Mail Website
Guest Editor
Department of Gastroenterology, Saitama Cancer Center, Saitama 362-0806, Japan
Interests: gastric cancer

Special Issue Information

Dear Colleagues,

Gastric cancer (GC) is the fifth most common and fourth most deadly cancer worldwide. The treatment of advanced gastric cancer has significantly developed over the last few years. As immune checkpoint inhibitors, anti-PD-1 antibodies have improved the prognosis of patients with metastatic GC. As a type of molecular target therapy, trastuzumab deruxtecan (T-Dxd), an antibody drug conjugate (ADC) for HER2, has shown significantly better outcomes compared with the physician’s choice of chemotherapy as later-line treatment in HER2-positive GC patients. In addition, other molecular target drugs, such as claudin 18.2 and FGFR2b, in combination with chemotherapy have shown promising outcomes in HER2-negative GC patients.  

This Special Issue will highlight the recent advances in immunotherapy, molecular target therapy, and other potential treatments for advanced GC. Manuscripts that focus on comprehensive literature reviews of treatment, including peri-operative or systemic chemotherapy, for advanced GC patients are welcome. Other topics may also be of interest and will be considered.

Prof. Dr. Yasuhide Yamada
Dr. Naoki Takahashi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gastric cancer
  • immunotherapy
  • anti-PD-1 antibody
  • trastuzumab deruxtecan
  • Claudin 18.2, zolbetuximab
  • FGFR2b
  • Bemarituzumab
  • neoadjuvant chemotherapy
  • adjuvant chemotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

21 pages, 820 KiB  
Review
Claudin18.2 in Advanced Gastric Cancer
by Rin Inamoto, Naoki Takahashi and Yasuhide Yamada
Cancers 2023, 15(24), 5742; https://doi.org/10.3390/cancers15245742 - 07 Dec 2023
Cited by 1 | Viewed by 2289
Abstract
Globally, the fifth most common cancer and the fourth leading cause of cancer-related mortality is gastric cancer (GC). Recent clinical trials on solid tumors enrolled patients who possess druggable genetic alterations, protein expression, and immune characteristics. In gastric or gastroesophageal junction (GEJ) cancers, [...] Read more.
Globally, the fifth most common cancer and the fourth leading cause of cancer-related mortality is gastric cancer (GC). Recent clinical trials on solid tumors enrolled patients who possess druggable genetic alterations, protein expression, and immune characteristics. In gastric or gastroesophageal junction (GEJ) cancers, trastuzumab combined with first-line chemotherapy in human epidermal growth factor receptor 2 (HER2)-positive patients and ramucirumab combined with second-line paclitaxel remarkably prolonged overall survival (OS) compared with chemotherapy alone, according to phase 3 trial results. Recently, immune checkpoint inhibitor (ICI) monotherapy was approved as third- or later-line treatment. Chemotherapy plus ICIs as first-line treatment exhibited improved survival compared with chemotherapy alone in HER2-negative patients according to Checkmate 649 trial results. Conversely, systemic chemotherapy prognosis remains poor. although some patients may achieve durable response to treatment and prolonged survival in advanced GC. Recently, a first-in-class, chimeric immunoglobulin G1 monoclonal antibody (zolbetuximab) that targets and binds to claudin 18 isoform 2 (CLDN18.2) has emerged as a new target therapy in GC treatment. Global phase Ⅲ trials revealed that the addition of zolbetuximab to first-line chemotherapy prolonged OS in CLDN18.2-positive and HER2-negative GC patients. This review summarizes recent clinical trials of CLDN18.2-targeted therapy. Full article
(This article belongs to the Special Issue Feature Review Papers on Advanced Gastric Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Review

22 pages, 2681 KiB  
Systematic Review
Clinical Features of Gastric Signet Ring Cell Cancer: Results from a Systematic Review and Meta-Analysis
by Mariagiulia Dal Cero, Maria Bencivenga, Drolaiz H. W. Liu, Michele Sacco, Mariella Alloggio, Kelly G. P. Kerckhoffs, Federica Filippini, Luca Saragoni, Mar Iglesias, Anna Tomezzoli, Fátima Carneiro, Heike I. Grabsch, Giuseppe Verlato, Lorena Torroni, Guillaume Piessen, Manuel Pera and Giovanni de Manzoni
Cancers 2023, 15(21), 5191; https://doi.org/10.3390/cancers15215191 - 28 Oct 2023
Viewed by 1252
Abstract
Background: Conflicting results about the prognostic relevance of signet ring cell histology in gastric cancer have been reported. We aimed to perform a meta-analysis focusing on the clinicopathological features and prognosis of this subgroup of cancer compared with other histologies. Methods: A systematic [...] Read more.
Background: Conflicting results about the prognostic relevance of signet ring cell histology in gastric cancer have been reported. We aimed to perform a meta-analysis focusing on the clinicopathological features and prognosis of this subgroup of cancer compared with other histologies. Methods: A systematic literature search in the PubMed database was conducted, including all publications up to 1 October 2021. A meta-analysis comparing the results of the studies was performed. Results: A total of 2062 studies referring to gastric cancer with signet ring cell histology were identified, of which 262 studies reported on its relationship with clinical information. Of these, 74 were suitable to be included in the meta-analysis. A slightly lower risk of developing nodal metastases in signet ring cell tumours compared to other histotypes was found (especially to undifferentiated/poorly differentiated/mucinous and mixed histotypes); the lower risk was more evident in early and slightly increased in advanced gastric cancer. Survival tended to be better in early stage signet ring cell cancer compared to other histotypes; no differences were shown in advanced stages, and survival was poorer in metastatic patients. In the subgroup analysis, survival in signet ring cell cancer was slightly worse compared to non-signet ring cell cancer and differentiated/well-to-moderately differentiated adenocarcinoma. Conclusions: Most of the conflicting results in signet ring cell gastric cancer literature could be derived from the lack of standardisation in their classification and the comparison with the different subtypes of gastric cancer. There is a critical need to strive for a standardised classification system for gastric cancer, fostering clarity and coherence in the forthcoming research and clinical applications. Full article
(This article belongs to the Special Issue Feature Review Papers on Advanced Gastric Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop